ARTICLE | Clinical News
Zelboraf vemurafenib regulatory update
February 27, 2012 8:00 AM UTC
The European Commission approved an MAA from Roche for Zelboraf vemurafenib to treat unresectable or metastatic melanoma in patients with BRAF V600 mutations. Roche already has CE Mark approval in Eu...